Pulse nav.journalClub 活発な議論トレンド探索研究者

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

ホーム探索 nav.journalClub トレンド

⌘+K

© Synapse Social LLC, 2026

プライバシーポリシー

Histone Deacetylase Inhibitors in Cancer Therapy | Synapse

October 14, 2009

癌治療におけるヒストン脱アセチル化酵素阻害剤

Key Points

Key points are not available for this paper at this time.

Abstract

HDAC阻害剤は複数の癌に対して単独薬剤としての効果を持つ重要な新興治療法であり、併用使用においても大きな可能性を秘めています。

AIに質問

Like

Bookmark

Share

Cite This Study

Lane et al. (Wed,) はこの問題について研究しました。

synapsesocial.com/papers/69d985ffe6ab964fb0835e70 https://doi.org/https://doi.org/10.1200/jco.2009.22.1291

AIに質問

Like

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy2005 · 142 citations
2Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies2005 · 24 citations
3Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: A California Cancer Consortium study2007 · 9 citations
4N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)2007 · 15 citations
5Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin2007 · 98 citations